title: Constitutively active 5-HT2/α1 receptors facilitate muscle spasms after human spinal cord injury.
abstract: In animals, the recovery of motoneuron excitability in the months following a complete spinal cord injury is mediated, in part, by increases in constitutive serotonin (5-HT2) and norepinephrine (α1) receptor activity, which facilitates the reactivation of calcium-mediated persistent inward currents (CaPICs) without the ligands serotonin and norepinephrine below the injury. In this study we sought evidence for a similar role of constitutive monoamine receptor activity in the development of spasticity in human spinal cord injury. In chronically injured participants with partially preserved sensory and motor function, the serotonin reuptake inhibitor citalopram facilitated long-lasting reflex responses (spasms) previously shown to be mediated by CaPICs, suggesting that in incomplete spinal cord injury, functional descending sources of monoamines are present to activate monoamine receptors below the lesion. However, in participants with motor or motor/sensory complete injuries, the inverse agonist cyproheptadine, which blocks both ligand and constitutive 5-HT2/α1 receptor activity, decreased long-lasting reflexes, whereas the neutral antagonist chlorpromazine, which only blocks ligand activation of these receptors, had no effect. When tested in noninjured control participants having functional descending sources of monoamines, chlorpromazine was effective in reducing CaPIC-mediated motor unit activity. On the basis of these combined results, it appears that in severe spinal cord injury, facilitation of persistent inward currents and muscle spasms is mainly mediated by the activation of constitutive 5-HT2 and α1 receptor activity. Drugs that more selectively block these constitutively active monoamine receptors may provide better oral control of spasticity, especially in motor complete spinal cord injury where reducing motoneuron excitability is the primary goal.
authors.affiliation: Centre for Neuroscience, Univ. of Alberta, 5-005 Katz Group - Rexall Centre, Edmonton, AB, Canada T6G 2E1.
authors.forename: Jessica M
authors.initials: JM
authors.lastname: D'Amico
authors.forename: Katherine C
authors.initials: KC
authors.lastname: Murray
authors.forename: Yaqing
authors.initials: Y
authors.lastname: Li
authors.forename: K Ming
authors.initials: KM
authors.lastname: Chan
authors.forename: Mark G
authors.initials: MG
authors.lastname: Finlay
authors.forename: David J
authors.initials: DJ
authors.lastname: Bennett
authors.forename: Monica A
authors.initials: MA
authors.lastname: Gorassini
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000328:Adult; D000368:Aged; D015306:Biogenic Monoamines / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D016022:Case-Control Studies; D002746:Chlorpromazine / Q000494:pharmacology; D015283:Citalopram / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons / Q000378:metabolism / Q000502:physiology; D009128:Muscle Spasticity / Q000378:metabolism / Q000503:physiopathology*; D018482:Muscle, Skeletal / Q000294:innervation / Q000503:physiopathology; D044402:Receptor, Serotonin, 5-HT2A / Q000378:metabolism*; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism*; D011999:Recruitment, Neurophysiological / Q000187:drug effects; D012018:Reflex / Q000187:drug effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D013119:Spinal Cord Injuries / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology*
chemical_list: D015306:Biogenic Monoamines; D002118:Calcium; D002746:Chlorpromazine; D015283:Citalopram; D018492:Dopamine Antagonists; D044402:Receptor, Serotonin, 5-HT2A; D018340:Receptors, Adrenergic, alpha-1; D017367:Selective Serotonin Reuptake Inhibitors